FONAR Announces First Fiscal 2014 Quarter Earnings Results

MELVILLE, NY--(Marketwired - Nov 15, 2013) - FONAR Corporation (NASDAQ: FONR)

First Fiscal 2014 Quarter net revenues increase 77% over First Fiscal Quarter 2013 to $16.8 million
First Fiscal 2014 Quarter net income increases 104% over First Fiscal Quarter 2013 to $3.6 million
Diluted Net Income Available to Common Stockholders for the First Fiscal 2014 Quarter was $0.37, an increase of 68% over First Fiscal Quarter 2013
FONAR records fifteenth straight quarter of positive net income and income from operations

FONAR Corporation (NASDAQ: FONR), The Inventor of MR Scanning™, reported its first quarter fiscal 2014 results for the quarter ended September 30, 2013. The Company's two industry segments are: development, manufacturing and servicing of the UPRIGHT® Multi-Position™ MRI, and management of Stand-Up® MRI (UPRIGHT® MRI) centers. The Company is known as the first Company to invent and manufacture an MRI (Magnetic Resonance) scanner. Leading the list of FONAR's most recent patented inventions is its technology enabling full weight-bearing MRI imaging, in contrast to the conventional weightless recumbent MRI, for the first time on all the gravity sensitive regions of the human anatomy, e.g. the spine, brain, hip, knee, ankle, foot, shoulder, and pelvis. The FONAR UPRIGHT® Multi-Position™ MRI scanner is the world's only MRI scanner licensed under FONAR's multiple UPRIGHT® MRI patents to scan all the patient's body parts in their normal fully weight-bearing UPRIGHT® position.

Financial Highlights

The management of diagnostic imaging center segment, consisting of Patient and Management fee revenues, increased 149% to $14.3 million for the quarter ended September 30, 2013, over the comparable quarter one year earlier ended September 30, 2012. The Company's total revenues were $16.8 million for the quarter ended September 30, 2013 an increase of 77% one year earlier when total revenues were $9.5 million.

The increase in revenues resulted in a 104% increase in net income to $3.6 million for the quarter ended September 30, 2013, as compared to $1.8 million for the quarter ended September 30, 2012.

Income from operations for the quarter ended September 30, 2013 was $4.0 million as compared to $1.9 million for the quarter ended September 30, 2012.

Basic net income per common share available to Common Stockholders for the quarter ended September 30, 2013 was $0.38, as compared to $0.23 for the quarter ended September 30, 2012. Diluted income per common share available to Common Stockholders for the quarter ended September 30, 2013 was $0.37, as compared to $0.22 for the quarter ended September 30, 2012.

Total assets were $75.6 million at September 30, 2013 as compared to $73.2 million at June 30, 2013.

Total liabilities were $35.3 million at September 30, 2013 as compared to $35.4 at June 30, 2013.

Total current liabilities were $22.4 million at September 30, 2013 as compared to $21.1 million at June 30, 2013.

At September 30, 2013, total cash and cash equivalents increased 17% to $9.2 million, as compared to $7.9 million at June 30, 2013.

Management Commentary

Raymond V. Damadian, M.D., president and chairman of Fonar Corporation, said: "We had understood that the acquisition of HDM would be a significant source of profitability. This has been the case and the Company's diluted earnings per share available for the common stockholder for the 1st quarter of Fiscal 2014 increased 68% to $0.37 when compared to one year earlier.

"There are more reasons why this acquisition makes a lot of sense," continued Dr. Damadian. "By combining the resources of HMCA and HDM, we will enjoy the benefits of economies of scale, shared administrative and technical expertise and capabilities, and joint marketing strategies. HMCA's 11 STAND-UP® MRIs together with HDM's 12 form a network of 23 FONAR weight-bearing MRI scanners, the largest in the world as compared to the conventional essentially weightless MRI.* Of course, we're not finished growing," said Dr. Damadian. "We will continue to pursue additional management contracts, primarily in New York and Florida."

"Our successful business model is made possible by the success of our current MRI scanner, the UPRIGHT® Multi-Position™ MRI," continued Dr. Damadian. "This scanner is extremely popular with patients who experience claustrophobia or can't lie down for long periods. However, patient comfort is only one side of this product. The much more compelling reason a patient would want to be scanned is to get the right diagnosis. This is the world's only scanner that can scan all body parts in their normal weight-bearing posture. It is essential to visualize the body in its normal weight-bearing positions in order to accurately diagnose the source of the patient's pain, so that the optimum treatment for the patient can be prescribed. In the weightless posture of the conventional recumbent MRI, it is impossible to accurately assess the patients' weight-bearing anatomic pathologies so they can be correctly treated. It is self-evident that if you can't see them you can't treat them. It is very common with the UPRIGHT® weight-bearing MRI to encounter disc herniations and spinal dislocations that were not visible in the conventional "weightless" recumbent MRI position.*"

*The calculated weight load of a 180 lb. upright patient on the L3/4 lumbar vertebral disc is 45.5 lbs. per square inch as compared to a weight-load of 4.5 lbs per square inch in a conventional recumbent "weightless" MRI which is only bearing 1/10th the weight the disc is bearing throughout the course of its common upright every day activities.

"This past April 6th we held 'Symposium 2013' in New York City. The symposium was called 'The Cranio-Cervical Syndrome (CCS): The Vulnerability of the Human Neck and Its Impact on Cerebrospinal Fluid (CSF) Flow'," said Dr. Damadian. "There is a pandemic degree of injuries to the neck and head, resulting from the 1.2 million automobile whiplash injuries occurring each year in the United States that are currently going unrecognized. The principal purpose of Symposium 2013 was to bring the existence of this Cranio-Cervical Syndrome to the attention of the medical community and to the general populace. We will publish early next year a monograph containing the presentation of the faculty who presented at the conference. I urge all interested parties to see the presentations which are found on line at: www.youtube.com/user/FonarMRIimaging."

"Our understanding of the Cranio-Cervical Syndrome (CCS) and the vulnerability of the human neck and its impact on cerebrospinal fluid (CSF) flow began with our UPRIGHT® MRI research and findings on multiple sclerosis," said Dr. Damadian. "On September 20, 2011, I and co-author, FONAR scientist David Chu, PhD., published a paper titled "The Possible Role of Cranio-Cervical Trauma and Abnormal CSF Hydrodynamics in the Genesis of Multiple Sclerosis," in the journal Physiological Chemistry and Physics and Medical NMR (Sept. 20, 2011, 41: 1-17), found at http://www.fonar.com/. With this new understanding of the role that cervical trauma plays in the etiology of disease, it is imperative to certify that the sustained neck or head injuries of professional athletes such as NFL football players, whiplash patients and others with severe neck trauma, have not resulted in any obstructions of CSF flow, which would eventually lead to the symptomatology of the Cranio-Cervical Syndrome."

"The Company is fortunate to have as its flagship product the FONAR UPRIGHT® Multi-Position™ MRI," continued Dr. Damadian. "This is truly a unique technology producing exquisite images in all positions of the body. It not only yields a whole new treasure of new medical applications in such calamitous medical categories as multiple sclerosis, and other dementia, but it also possesses the strong potential to provide fresh new insights into the debilitating chronic consequences of sports injuries, the current epidemic of automobile whiplash injuries, all spine injuries, and more diseases yet to be unearthed."

About FONAR

FONAR (NASDAQ: FONR), Melville, NY, The Inventor of MR Scanning™, was incorporated in 1978, and is the first, oldest and most experienced MRI company in the industry. FONAR introduced the world's first commercial MRI in 1980, and went public in 1981. Since its inception, nearly 300 recumbent-OPEN MRIs and 157 UPRIGHT® Multi-Position™ MRI scanners have been installed worldwide. FONAR's stellar product is the UPRIGHT® MRI (also known as the Stand-Up® MRI), the only whole-body MRI that performs Position™ imaging (pMRI™) and scans patients in numerous weight-bearing positions, i.e. standing, sitting, in flexion and extension, as well as the conventional lie-down position. The FONAR UPRIGHT® MRI often sees the patient's problem that other scanners cannot because they are lie-down and "weightless" only scanners. The patient-friendly UPRIGHT® MRI has a near-zero claustrophobic rejection rate by patients. As a FONAR customer states, "If the patient is claustrophobic in this scanner, they'll be claustrophobic in my parking lot." Approximately 85% of patients are scanned sitting while they watch a 42" flat screen TV. FONAR is headquartered on Long Island, New York.

UPRIGHT® and STAND-UP® are registered trademarks and The Inventor of MR Scanning™, Full Range of Motion™, Multi-Position™, Upright Radiology™, The Proof is in the Picture™, True Flow™, pMRI™, Spondylography™, Dynamic™,Spondylometry™, CSP™, and Landscape™, are trademarks of FONAR Corporation.

This release may include forward-looking statements from the company that may or may not materialize. Additional information on factors that could potentially affect the company's financial results may be found in the company's filings with the Securities and Exchange Commission.


FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(AMOUNTS AND SHARES IN THOUSANDS,EXCEPT PER SHARE AMOUNTS)
(UNAUDITED)

ASSETS

			September 30, 2013			June 30, 2013*
Current Assets:
	Cash and cash equivalents		$	9,238		$	7,871
	Accounts receivable - net			5,026			4,444
	Accounts receivable - related party			90			--
	Medical receivable - net			8,552			8,126
	Management and other fees receivable - net			12,075			11,466
	Management and other fees receivable - related medical practices - net			2,743			2,382
	Inventories			2,126			2,077
	Prepaid expenses and other current assets			1,292			1,500
		Total Current Assets		41,142			37,866
	Property and equipment - net			17,067			17,524
	Goodwill			1,767			1,767
	Other intangible assets - net			11,608			11,904
	Deferred income tax asset			2,936			2,936
	Other assets			1,078			1,154
		Total Assets	$	75,598		$	73,151



FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(AMOUNTS AND SHARES IN THOUSANDS,EXCEPT PER SHARE AMOUNTS)
(UNAUDITED)

LIABILITIES AND STOCKHOLDERS' EQUITY

			September 30, 2013			June 30, 2013
Current Liabilities:
	Current portion of long-term debt and capital leases			3,154			2,886
	Accounts payable			2,695			2,752
	Other current liabilities			9,011			8,636
	Unearned revenue on service contracts			5,516			4,965
	Unearned revenue on service contracts - related party			83			--
	Customer advances			1,917			1,858
	Income tax payable			--			20
		Total Current Liabilities		22,376			21,117
	Long-Term Liabilities:
	Due to related medical practices			230			231
	Long-term debt and capital leases, less current portion			11,649			12,887
	Deferred income tax liability			462			462
	Other liabilities			625			654
		Total Long-Term Liabilities		12,966			14,234
		Total Liabilities		35,342			35,351



FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(AMOUNTS AND SHARES IN THOUSANDS,EXCEPT PER SHARE AMOUNTS)
(UNAUDITED)

LIABILITIES AND STOCKHOLDERS' EQUITY (Continued)

STOCKHOLDERS' EQUITY:			September 30, 2013			June 30, 2013
	Class A non-voting preferred stock $.0001 par value; 453 shares authorized at September 30, 2013 and June 30, 2013, 313 issued and outstanding at September 30, 2013 and June 30, 2013			--			--
	Preferred stock $.001 par value; 567 shares authorized at September 30, 2013 and June 30, 2013, issued and outstanding - none			--			--
	Common Stock $.0001 par value; 8,500 shares authorized at September 30, 2013 and June 30, 2013, 5,999 and 5,981 issued at September 30, 2013 and June 30, 2013, respectively; 5,988 and 5,969 outstanding at September 30, 2013 and June 30, 2013, respectively			1			1
	Class B Common Stock (10 votes per share) $.0001 par value; 227 shares authorized at September 30, 2013 and June 30, 2013; .146 issued and outstanding at September 30, 2013 and June 30, 2013			--			--
	Class C Common Stock (25 votes per share) $.0001 par value; 567 shares authorized at September 30, 2013 and June 30, 2013, 383 issued and outstanding at September 30, 2013 and June 30, 2013			--			--
	Paid-in capital in excess of par value			174,628			174,499
	Accumulated deficit			(157,218	)		(159,655	)
	Notes receivable from employee stockholders			(53	)		(55	)
	Treasury stock, at cost - 12 shares of common stock at September 30, 2013 and June 30, 2013			(675	)		(675	)
	Total Fonar Corporation Stockholder Equity			16,683			14,115
	Noncontrolling interests			23,573			23,685
	Total Stockholders' Equity			40,256			37,800
	Total Liabilities and Stockholders' Equity		$	75,598		$	73,151


FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(AMOUNTS AND SHARES IN THOUSANDS,EXCEPT PER SHARE AMOUNTS)
(UNAUDITED)
		FOR THE THREE MONTHS ENDED SEPTEMBER 30,
REVENUES		2013			2012
	Product sales - net	$	28		$	1,041
	Service and repair fees - net		2,512			2,709
	Service and repair fees - related parties - net		28			27
	Patient fee revenue, net of contractual allowances and discounts		5,827			--
	Provision for bad debts for patient fee		(2,040	)		--
	Management and other fees - net		8,143			3,769
	Management and other fees - related medical practices - net		2,333			1,965
	Total Revenues - Net		16,831			9,511
COSTS AND EXPENSES
	Costs related to product sales		48			1,056
	Costs related to service and repair fees		544			865
	Costs related to service and repair fees - related parties		6			9
	Costs related to patient fee revenue		1,848			--
	Costs related to management and other fees		5,075			2,171
	Costs related to management and other fees - related medical practices		1,219			817
	Research and development		395			330
	Selling, general and administrative		3,737			2,212
	Provision for bad debts		(94	)		175
	Total Costs and Expenses		12,778			7,635
	Income From Operations		4,053			1,876
	Interest Expense		(243	)		(76	)
	Investment Income		61			59
	Other Expense		(151	)		(9	)
	Income Before Provision for Income Taxes and Noncontrolling Interests		3,720			1,850
	Provision for Income Taxes		100			72
	Net Income		3,620			1,778
	Net Income - Noncontrolling Interests		(1,183	)		(326	)
	Net Income - Controlling Interests	$	2,437		$	1,452
	Net Income Available to Common Stockholders	$	2,277		$	1,355
	Net Income Available to Class A Non-Voting Preferred Stockholders	$	119		$	72
	Net Income Available to Class C Common Stockholders	$	41		$	25
	Basic Net Income Per Common Share Available to Common Stockholders	$	0.38		$	0.23
	Diluted Net Income Per Common Share Available to Common Stockholders	$	0.37		$	0.22
	Basic and Diluted Income Per Share - Common C	$	0.11		$	0.06
	Weighted Average Basic Shares Outstanding - Common Stockholders		5,978			5,901
	Weighted Average Diluted Shares Outstanding - Common Stockholders		6,106			6,029
	Weighted Average Basic Shares Outstanding - Class C Common		383			383
	Weighted Average Diluted Shares Outstanding - Class C Common		383			383